A Study of IMC-A12 (Cixutumumab) With and Without Other Standard Chemotherapies in Participants With Lung Cancer Who Have Not Received Chemotherapy Before

Status:
Completed

Trial end date:
2012-05-01

Target enrollment:

Participant gender:

The purpose of this study is to determine the number of participants whose cancer shrinks or disappears after treatment on the study.

Phase 2

Eli Lilly and Company
ImClone LLC

Antibodies, Monoclonal
Carboplatin
Cetuximab
Cisplatin
Gemcitabine